Clinical Trial Update: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial to evaluate radium-223 in combination with docetaxel for prostate cancer. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING